Global Leukemia Therapeutics Market is Estimated to Value Over USD 18.6 Billion by 2026 End

  • 07 Oct 2019

Global Leukemia Therapeutics Market is estimated to value over USD 18.6 billion by 2026 end and register a CAGR of over 5.8% during the forecast period 2019 to 2026.


The global leukemia therapeutics market growth is driven by the increasing prevalence of persistent diseases globally. Leukemia is diagnosed by the spread of chronic and acute disease that is frequently caused owing to the radiation exposure, environmental factors and unhealthy lifestyle choices. The high unmet needs pertaining to early diagnosis and treatment of leukemia and rising aged population base are the important factors steering the market growth. As per the report by the World Health Organization (WHO), leukemia is the most prevalent blood cancer, especially in males, all across the world.


The Acute Myeloid Leukemia Segment Dominated the Global Market

The Acute myeloid leukemia segment subjugated the therapeutics market due to a rise in the number of incidences, high rates of drugs consumed for treatments and quick absorption of second-gen tyrosine inhibitors. The leukemia diagnosis segment is researched pertaining to MRI, biopsy and CT scan. For chemotherapy treatments and chronic lymphatic leukemia radiation therapy were the most widely used techniques in 2015. The CVAD treatment subjugated the global market of chemotherapy treatments in 2014. The bone marrow transplant and stem cell therapy are the emerging global leukemia therapeutics market trends and are projected to stimulate the proliferation of the market. The Drugs used for leukemia treatment are Omapro, Vidaza, Gleevec, GA101, Vasaroxine, Tosedosat, Marqibo, Sapacitabine, Bosutinib, Dacogen, Graspa, and Revlimid. Gleevec was one of the main contributors to the market growth in 2013.

The North America region held the largest global leukemia therapeutics market in 2016 owing to the ever-increasing awareness amongst patients, advancements in technology, government policies that bolster the rise in investments and incentives, the systematic infrastructure of healthcare systems are the important factors contributing to its dominance. The European region is the second-largest market owing to the introduction of new brands such as Arragon, Tasigna, Clolar and Sprycel and a wider product presence without any expiration of the patent.

Key market players included in the global leukemia therapeutics industry are Novartis AG, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Sanofi, Pfizer, Amgen, Gilead Sciences, Takeda, Celgene. 

Novartis is currently leading the global leukemia therapeutics market, due to its innovative therapies and strong sales channel. The company infused over 17% of its total revenue over the research and development sector. Novartis, in May 2018, announced its CAR-T cell therapy for the second indication patient treatment with refractory or relapsed large B-cell lymphoma. With the announcement of Kymriah, Novartis is now a major market player of immunotherapies for treating leukemia.


Global Leukemia Therapeutics Market Segmentation:

By Type of Leukemia

  • Chronic Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Acute Lymphocytic Leukemia 
  • Acute Myeloid Leukemia

By Treatment Type

  • Targeted Drugs & Immunotherapy
  • Chemotherapy

By Molecule Type

  • Small Molecules
  • Biologics

By Mode of Administration

  • Oral Mode
  • Injectable Mode

By Gender

  • Males
  • Females

By Region

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World


FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth


Objectives of the Study:

  • To provide with an exhaustive analysis on the global leukemia therapeutics market by type of leukemia, by treatment type, by molecule type, by mode of administration, by gender and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies


Get unlimited analyst support and customise this study further to your requirements, contact